APD811 2018-09-07T13:56:35+00:00

Clinical Trials

August 18, 2015

A Randomized, Double-blind, Parallel-group, Placebo-controlled Phase 2 Trial of APD811, an Oral IP Receptor Agonist, in Patients with Pulmonary Arterial Hypertension

  • Study Sponsor: Arena Pharmaceuticals, Inc.
  • Status: Recruiting
  • Design: Placebo-controlled
    Background treatment allowed
  • Age range (years): from 18 to 75
  • Type of PH
    • IPAH
    • Heritable – APAH
    • CTD – APAH
    • CHD – APAH
    • Toxic – APAH
    • HIV – APAH
  • Study Duration for individual patient: 25 weeks
  • Contact: Brian Raether, phone: 858-453-7200, ext. 1732
  • Listing on clinicaltrials.gov